CD BioGlyco aims to help clients conduct biomedical research, understand the molecular basis of human disease, and develop new and more effective methods of diagnosis, prevention, and therapeutic intervention. Therefore, we provide glycobiology disease model development service to research various diseases, and we have constructed diverse Disease Models, including:
Owing to ethical issues, we provide an in vitro glycobiology disease model and experimental systems, that are used to simulate and analyze various cellular processes, interactions, and responses under controlled conditions. In vitro cell models play a crucial role in research fields such as drug discovery, toxicology, and basic biological studies. We conduct functional screening of carbohydrates and their related compounds using a diverse range of cell culture models. These different cell lines have emerged as an important model, offering physiological relevance, and are highly useful for studying bioactivity, biotransformation, and toxicity. We have constructed a comprehensive library of carbohydrate-related compounds available for the client's selection. Clients can also provide compounds that they are interested in.
Our in vitro screening service is tailored to the client's specific needs. Clients can choose to furnish us with their preferred cell lines, allowing conducting research with cell types that align closely with their study objectives. We have also established a wide array of diverse cell culture models. By using our range of cell culture models, we will help clients address a wide variety of research interests and study goals in the field of glycobiology.
HeLa Cells-based In Vitro Screening Service
CD BioGlyco offers discovery and screening services for lead carbohydrate-related compounds with bioactivity using HeLa cells, catering to both cancer and other disease research. Our comprehensive screening, evaluations, and analysis will assist clients in understanding deeply the role of carbohydrates in disease.
3T3-L1 Cells-based In Vitro Screening Service
CD BioGlyco provides a 3T3-L1 cells-based model for studying glucose metabolism in vitro. Using differentiated 3T3-L1 cells, we will help clients investigate glucose uptake, lipid metabolism, gene expression, drug screening, and toxicity assessment.
Muscle Cells-based In Vitro Screening Service
Glucose metabolism also will be researched by muscle cells, including C2C12 and L6 cells. These cells differentiate into myotubes expressing insulin-responsive GLUT4, vital for glucose uptake. We offer comprehensive studies on glucose uptake mechanisms, including insulin-stimulated pathways. This cell model can be used for anti-diabetic compound screening to explore potential lead compounds for diabetes.
Hepatocyte-based In Vitro Screening Service
This service focuses on studying glucose metabolism using hepatic cell lines. We utilize hepatocytes to study the intricate mechanisms of glycolysis, glycogen synthesis, and gluconeogenesis, fundamental processes that play a critical role in the regulation of glucose metabolism. This cell model can be combined with our animal models to screen for potential substances with anti-diabetic and anti-obesity properties, among other metabolic disorders.
Insulin Target Cells-based In Vitro Screening Service
Insulin target cells-based in vitro screening services are specifically designed to study insulin release and signal transduction. It is important for understanding the regulation mechanism of blood glucose levels and insulin resistance. CD BioGlyco offers efficient methods for screening insulin target cell in vitro through high-throughput screening strategies.
Intestinal Cells-based In Vitro Screening Service
We culture intestinal cells in a glycans mixture for incubation to test the accumulation of glycans in these cells. To ascertain specific glycan accumulation, we employ reverse transcription-polymerase chain reaction (RT-PCR) to detect glycan-related gene expression. This service helps to study glycan interactions with intestinal cells for the exploration of potential targets.
THP-1 Monocyte-based In Vitro Screening Service
We culture THP-1 cells, derived from human peripheral blood, to mimic primary human monocytes in morphology and function. They replicate inflammatory and signaling pathways in chronic high-glucose environments and are an ideal model for studying immunity and inflammation. Besides, we will construct a THP-1 knockout model to investigate the pivotal genes linked to pathogen clearance by macrophages.
Vero Cells-based In Vitro Screening Service
At CD BioGlyco, a Vero cells-based model is utilized to evaluate the impact of carbohydrates on cell proliferation, metabolism, and toxicity. We culture and expose Vero cells to varying concentrations of sugar solutions to observe changes in cell viability, morphology, and functionality. Moreover, Vero cells can also be employed to investigate the interaction between carbohydrates and viral infections.
Besides, gene editing techniques, including gene knock-out and gene knock-in, are also employed to delete or add specific glycogene to cells for screening and studying purposes. Through our strategy, we will precisely manipulate strategy within cells, screening for genes associated with glycosylation diseases and exploring the functions and impacts of glycogene within cellular contexts.
Technology: MTT assay, Glucose uptake assay
Journal: Journal of applied pharmaceutical science
Published: 2015
Results: Terminalia bellirica is a tree belonging to the Combretaceae family and commonly known as "dhandrika" in Tamil. In this study, authors conducted cytotoxicity screening of the ethanolic extract from Terminalia bellirica fruits using the MTT assay. Additionally, they assessed glucose uptake using various cell lines, including L-6 and 3T3 and compared them with normal healthy Vero cell lines. The results indicated that the extracts showed no cytotoxic effects and demonstrated significant potential for glucose uptake, with the ethanolic extract exhibiting particularly promising results. The study also compared the effects of the extracts with those of insulin and metformin, standard antidiabetic drugs, showing comparable or even better glucose uptake activity.
Fig.1 In vitro cytotoxic effect of Terminalia bellirica using MTT Assay. (Das, et al., 2015)
CD BioGlyco utilizes the power of glycobiology in studying human diseases and advancing drug discovery and development. In addition to our in vitro services, we also offer an In Vivo Glycobiology Disease Model Screening Service, where we utilize animal models to validate findings from in vitro studies. We combine in vitro and in vivo strategies to provide more comprehensive research for glycobiology disease. Moreover, our research team of experts can tailor disease models to mimic specific glycobiology diseases to conduct more precise drug screening and target identification. Contact us today to arrange your upcoming in vitro study.
Reference
